Supplementary Information

Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies

Garber et al.





Supplementary Figure 2. Plasma viremia following penile SHIV_{SF162P3} infection

(A) Peak plasma viremia or (B) vRNA area under the curve through 7 weeks post-infection following penile SHIV infection among 10-1074-treated macaques or untreated controls. At each timepoint for each macaque, vRNA values were determined as the average of duplicate samples. Animal group sizes were 6 (10-1074) or 10 (Control), as shown. Lines denote geometric means for each group. NS = not significant (Mann-Whitney test, two-sided).





repeated penile SHIV_{SF162P3} challenges

Rhesus SHIV_{SF162P3} Env-specific antibody responses were evaluated in plasma samples via ELISA among macaques administered 10-1074, challenged repeatedly with SHIV_{SF162P3} via the penis, who exhibited SHIV breakthrough following 13-19 weekly challenges (A) or 5 weekly challenges (B). ELISA plates (96-well, high binding plates (Corning)) were coated overnight with 1 μ g SHIV_{SF162P3} Env (gp120) (Immune Technology Corp.) per well, then blocked with phosphate buffered saline containing 1% bovine serum albumin (PBS-1%BSA). Plasma samples were diluted 1:50 in PBS-1%BSA, added to the plates (100 μ l per well) and

incubated for 1.5 hour at 37°C. Plates were washed and incubated with mouse anti-rhesus IgG heavy chain-horseradish peroxidase (HRP) preadsorbed (Abcam) for 30 minutes at 37°C. Plates were washed and assayed for HRP activity by the addition of tetramethylbenzidine (1-Step Ultra TMB, ThermoFisher). Color development was arrested via the addition of sulfuric acid to a final concentration of 1N and absorbance at 450nm was measured using a BioTek ELx808 plate reader. Plasma samples were assayed in triplicate - individual values (circles) and mean values (bars) are shown. Panels (A) and (B) show representative results from one of two independent experiments.

macaque pla	asma follow	ing subcuta	ineous inj	ection at w	eek (-1)	
10-1074						
Week	10-24	10-27	10-90	10-139	10-233	11-141
-1	<0.10	<0.10	<0.10	<0.10	<0.10	<0.10
0	40.90	24.60	27.20	27.50	35.50	60.00
2	24.30	14.20	16.40	24.70	23.00	18.80
4	12.40	6.40	10.00	<0.10	13.10	9.50
5				<0.10		
6	6.10	3.40	6.20		11.00	4.20
8	3.40	2.10	2.60		3.60	3.20
10	3.20	1.00	1.70		3.40	1.70
12	1.20	0.70	0.80		2.20	0.70
13		0.60				0.70
14	0.80	0.70	0.40		1.10	
16	0.50		0.40		0.60	
17	0.30				0.60	
18	0.40		0.20			
19			0.20			

Supplementary Table 1. 10-1074 antibody concentration (μ g ml⁻¹) in macaque plasma following subcutaneous injection at week (-1)

3BNC117							
		RQ-					
Week	RQ-02E035	02E060	RQ-8433	RQ-8684	RQ-8918		
-1	<0.24	<0.24	<0.24	<0.24	<0.24		
0	5.20	6.00	2.00	8.50	7.90		
1	3.60	4.20	1.00	5.60	4.30		
2	2.90	2.20	0.60	3.30	3.40		
3	1.90	1.40	<0.24	4.20	1.60		
4	1.10	0.60	<0.24	1.80	1.20		
5	0.70	0.50	<0.24	0.60	0.50		
6	0.80	<0.24	<0.24	0.50	0.30		
7	0.30	<0.24	<0.24	0.40	<0.24		
8	<0.24	<0.24	<0.24	<0.24	<0.24		
9	<0.24	<0.24	<0.24	<0.24	<0.24		

Supplementary Table 2. bNAb concentrations (µg ml⁻¹) in plasma of macaques co-administered 3BNC117 and 10-1074 via subcutaneous injections at week (-1)

10-1074

Week	RQ- 02E035	RQ- 02E060	RQ-8433	RQ-8684	RQ-8918
-1	<0.07	<0.07	<0.07	<0.07	<0.07
0	51.10	35.10	26.10	36.60	29.60
1	24.40	17.20	15.30	25.90	13.70
2	12.80	9.80	9.50	13.60	12.00
3	12.40	5.90	6.20	11.00	7.10
4	7.30	3.60	5.50	9.60	4.60
5	4.20	2.80	4.10	4.90	2.20
6	3.00	1.80	2.30	4.10	1.70
7	2.10	1.40	1.40	3.60	1.00
8	1.60	0.80	0.90	1.70	0.80
9	1.00	0.60	0.60	1.40	0.40
10	0.50	0.20	0.20	0.50	0.10
11	0.30	0.10	0.10	0.30	<0.07
12	0.20	<0.07	0.10	0.30	<0.07
13	0.10	<0.07	<0.07	0.20	<0.07
14	0.10	<0.07	<0.07	<0.07	<0.07
15	<0.07	<0.07	<0.07	<0.07	<0.07
16	<0.07	<0.07	<0.07	<0.07	<0.07
17	<0.07	<0.07	<0.07	<0.07	<0.07
18	<0.07	<0.07	<0.07	<0.07	<0.07

3BNC117						
Week	07-155	RQ-8011	RQ-8428	RQ-8944	RQ-9200	RQ-9207
-1	<0.24	<0.24	<0.24	<0.24	<0.24	<0.24
0	4.90	8.30	8.70	1.70	7.70	10.50
1	2.70	5.20	5.40	1.60	6.90	4.50
2	1.80	3.70	3.60	0.90	5.90	2.90
3	0.90	1.60	2.40	0.70	2.60	1.30
4	0.40	0.60	1.00	0.40	2.10	0.80
5	<0.24	<0.24	1.10	0.30	1.80	0.50
6	<0.24	<0.24	0.70	<0.24	1.00	<0.24
7	<0.24	<0.24	0.30	<0.24	0.80	<0.24
8	<0.24	<0.24	<0.24	<0.24	<0.24	<0.24
9	<0.24	<0.24	<0.24	<0.24	<0.24	<0.24

Supplementary Table 3. 3BNC117 antibody concentration (μ g ml⁻¹) in plasma of macaques administered 3BNC117 singly via subcutaneous injection at week (-1)